The alarmin cytokines thymic stromal lymphopoietin (TSLP), interleukin (IL)-33 and IL-25 and are epithelial cell-derived mediators that contribute to the pathobiology and pathophysiology of asthma. Released from airway epithelial cells exposed to environmental triggers, the alarmins drive airway inflammation through the release of predominantly T2 cytokines from multiple effector cells. The upstream positioning of the alarmins is an attractive pharmacological target to block multiple T2 pathways important in asthma. Blocking the function of TSLP inhibits allergen-induced responses including bronchoconstriction, airway hyperresponsiveness and inflammation, and subsequent clinical trials of an anti-TSLP monoclonal antibody, tezepelumab, in asthma patients demonstrated improvements in lung function, airway responsiveness, inflammation, and importantly, a reduction in the rate of exacerbations. Notably, these improvements were observed in patients with T2-high and with T2-low asthma. Clinical trials blocking IL-33 and its receptor ST2 have also shown improvements in lung function and exacerbation rates, however the impact of blocking the IL-33/ST2 axis in T2-high versus T2-low asthma is unclear. To date there is no evidence that IL-25 blockade is beneficial in asthma. Despite considerable overlap in the cellular functions of IL-25, IL-33 and TSLP, they appear to have distinct roles in the immunopathology of asthma.
This article is protected by copyright. All rights reserved.